Roivant autoimmune drug succeeds in eye condition; company to buy back $1.5 billion in stock; Verve Therapeutics ‘pauses’ tests of its gene editor for heart disease and prioritizes a backup treatment

Taking stock of the drug industry, from the lab to the medicine chest

April 2, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Drew Angerer/Getty Images STAT+ | Roivant autoimmune drug succeeds in eye condition; company to buy back $1.5 billion in stock A Roivant subsidiary is studying the drug, called brepocitinib, in a number of inflammatory autoimmune conditions. By Andrew Joseph STAT+ | Verve Therapeutics 'pauses' tests of its gene editor for heart disease and prioritizes a backup treatment The company said it has already received approval from Canadian and European regulators to begin a clinical trial of a similar gene-editing compound. By Matthew Herper STAT+ | Gritstone Bio says personalized cancer vaccine falls short in key trial The company said it plans to launch a Phase 3 study in 2025, but that will likely be dependent on having adequate funds. By Jason Mast Ryan Pierse/Getty Images STAT+ | The biotech scoreboard for the second quarter: 32 stock-moving events to watch Among other readouts, Sage Therapeutics will report study results on two drugs and Pfizer is expected to announce results from a gene therapy study. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser